PREVU* life insurance trial
This article was originally published in The Tan Sheet
A 25,000-patient study evaluating PREVU* LT in the life insurance testing market is expected to begin in the second quarter of 2005, International Medical Innovations announces May 10. The PREPARE study (PREVU Predicts Atherosclerosis Risk & Events) will test life insurance applicants with the product and compare the results to "traditional risk assessment measures," IMI says. PREVU* LT is the lab-processed version of the company's skin sterol test, which measures cholesterol levels by testing skin tissues. Entering the insurance market offers an opportunity to the firm because a "significant number" of the 13.5 mil. individuals who purchased life insurance policies in 2003 did not have a cardiovascular disease assessment, IMI says. The company reached a licensing agreement last year with McNeil's consumer division that includes working to develop an OTC version of the product (1"The Tan Sheet" June 7, 2004, p. 10)...
You may also be interested in...
McNeil Consumer Health is seeking to leverage the potential Rx-to-OTC switch of J&J/Merck's Mevacor (lovastatin) with an agreement to license International Medical Innovations' predictive tests for coronary artery disease (CAD)
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.